Regeneron (REGN) Misses Q4 EPS by 48c

Regeneron (NASDAQ: REGN) reported Q4 EPS of $2.83, $0.48 worse than the analyst estimate of $3.31. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.17 billion.

In the fourth quarter of 2015, net sales of EYLEA in the United States increased 44% to $746 million from $518 million in the fourth quarter of 2014. For the full year of 2015, net sales of EYLEA in the United States increased 54% to $2.676 billion from $1.736 billion for the full year 2014. Overall distributor inventory levels remained within the Company's one- to two-week targeted range.

For earnings history and earnings-related data on Regeneron (REGN) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• RBC cuts Northrop Grumman rating on slower growth, cautious defense outlook
• Regeneron drug shows muscle preservation in GLP-1 weight loss trial